Friday 6 November 2026 Export RXRX’s income statement to Excel — free account

Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024.

Revenue: +258.5%
EPS: +39.1%
Free cash flow: +33.8%
Total debt: −99.2%

Quarter to September 2026, against a year earlier

Revenue growth 5 yrs

3.59 0.09 +2.57%

Follow RXRX

Alert me

Market cap: $2.2B
P/E: 0.0×
Fwd P/E: −4.6×
Dividend yield: —
F-score: 3/9
Altman Z: 0.37
Beneish M: −1.72
Dividend safety: n/a

Overview

Recursion Pharmaceuticals, Inc. (RXRX) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Recursion Pharmaceuticals, Inc. (RXRX) trades at a P/S ratio of 27.9×. Over the past ten years it has ranged from 17.0× (March 2026) to 648× (July 2021); the current reading is higher than 13% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/RXRX/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Recursion Pharmaceuticals, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/RXRX/metrics/ps-ratio">Recursion Pharmaceuticals, Inc. (RXRX) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	24.5×	(22.22%)
FY2024	31.5×	(31.55%)
FY2023	46.0×	38.36%
FY2022	33.3×	(88.86%)
FY2022	299×	5.25%
FY2021	284×	154.27%
FY2021	112×	0.00%
FY2020	112×	0.00%
FY2020	112×	0.00%
FY2019	112×	0.00%

Period	P/S ratio	Change
Sep 2026	32.9×	(7.74%)
Jun 2026	35.6×	45.58%
Mar 2026	24.5×	(0.15%)
Dec 2025	24.5×	(50.92%)
23 more quarters	Free account

Against its own ten years

Low 17.0× High 648×

Ten-year median 38.4×

Current reading's percentile 13

Company	P/S ratio
PHVS Pharvaris N.V. compare	n/m
MBX MBX Biosciences, Inc. compare	n/m
BHVN Biohaven Ltd. compare	2.1×
ADMA ADMA Biologics Inc compare	5.7×
VCEL Vericel Corporation compare	8.1×
RXRX Recursion Pharmaceuticals, Inc.	27.9×
PVLA Palvella Therapeutics, Inc. compare	54.1×
NAMS NewAmsterdam Pharma Company N.V. compare	91.1×
CLDX Celldex Therapeutics, Inc. compare	2,498×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Recursion Pharmaceuticals, Inc. (RXRX) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on RXRX

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on RXRX

Stockrow Weekly